During the past decade, Regional Clinical Oncology Dispensary conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 13 clinical trials were completed, i.e. on average, 61.9% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 10 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regional Clinical Oncology Dispensary" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Biocad" with 4 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored and "Amgen" with 3 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regional Clinical Oncology Dispensary" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator and "Institut de Recherches Internationales Servier" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Regional Clinical Oncology Dispensary" are "Psoriasis" (6 trials), "Atopic Dermatitis" (3 trials), "Neoplasms" (2 trials), "Adenomatous Polyps" (1 trials) and "Advanced or Inoperable Gastric Cancer" (1 trials). Many other conditions were trialed in "Regional Clinical Oncology Dispensary" in a lesser frequency.

Most popular intervention types in "Regional Clinical Oncology Dispensary" are "Drug" (27 trials), "Other" (5 trials), "Biological" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Paclitaxel" (5 trials), "BCD-100" (3 trials), "Baricitinib" (3 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Regional Clinical Oncology Dispensary" are 27 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Regional Clinical Oncology Dispensary". undefined are not yet recruiting, 1 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Regional Clinical Oncology Dispensary, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Regional Clinical Oncology Dispensary, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".